Personalis
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.
In Brief This Week: Personalis, Cytek, Interpace, Co-Diagnostics, Thermo Fisher, Bruker, More
News items for the week of Aug. 5, 2024.
Myriad Genetics, Personalis Cross-License MRD Technology
The companies inked an agreement to co-license their minimal residual disease technology in an effort to broaden testing access and boost adoption.
Personalis, Foresight Diagnostics Settle MRD Testing Patent Lawsuit
Foresight has agreed to pay royalties to Personalis for the use of certain patented methods related to tumor-informed minimal residual disease testing.
As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.
Dec 6, 2023